Clinical Trial

QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated December 6, 2024 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of the study is to evaluate the efficacy and safety of QR12000 75mg, QR12000 150mg and Sacubitril/valsartan 200mg in patients with moderate to severe essential hypertension.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-11-29.
Trial Details
NCT Number NCT06716970
Lead Sponsor Wuhan Createrna Science and Technology Co., Ltd
Conditions Essential Hypertension
Enrollment 810 participants
Start Date 2024-12-30
Primary Completion 2026-04-30 (estimated)
Study Completion 2027-02-28 (estimated)
Updated on ClinicalTrials.gov 2024-12-06